A Study of Local Administration of Autologous Mesenchymal Stromal Cells in Dysphonic Patients With Vocal Fold Scarring

Summary

The overall aim of the project is to develop a new method for treatment of untreatable severe hoarseness due to vocal fold scarring by local injection of autologous mesenchymal stromal cells (MSC). At present there is no lasting effective treatment for this condition which results in personal suffering, and often extended sick leave, change of work or unemployement for the patients. Based on the previous results the investigators expect the autologous MSC product KI-MSC-PL-204 to be a new effective treatment without side effects for many patients with severe hoarseness or aphonia due to vocal fold scarring.

Timeline

Start

2021-03-01

Primary completion

2025-01-01

Completion

2025-01-01

Publications

• Bergstrom Borlin E, Nygren U, Sodersten M, Granqvist S, Kadri N, Rasmusson Duprez I, Le Blanc K, Hertegard S. An open phase I/IIa study evaluating safety, patient-reported outcomes and voice function after surgery, local administration of mesenchymal stromal cells and voice training in patients with vocal fold scarring and dysphonia. Stem Cell Res Ther. 2026 Apr 19;17(1):146. doi: 10.1186/s13287-026-05022-4.

Drugs

Indications